BRAF and neoplasm: BRAF inhibitors have proven clinical activity in BRAF-mutant patients in other tumour locations, such as melanoma, but resistance emerges frequently due to a multitude of escape mechanisms, thereby necessitating combination treatment (Fig. 1b).